STOCK TITAN

Year-end report, May-April 2020/21

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

Elekta reported strong order growth in Q4 2021, totaling SEK 5,379 M (up 18% in constant currency). Despite challenges due to Covid, net sales rose slightly to SEK 3,667 M. Full-year performance showed gross order intake at SEK 17,411 M (up 6%) and net sales at SEK 13,763 M. EBITA increased to SEK 2,709 M with a margin of 19.7%. A proposed dividend of SEK 2.20 per share was announced. The company aims for over 7% net sales CAGR until 2024/25, and plans to expand EBIT margins.

Positive
  • Gross order intake in Q4 2021 was SEK 5,379 M, an 18% increase in constant currency.
  • Full-year gross order intake reached SEK 17,411 M, a 6% growth in constant currency.
  • EBITA for the full year was SEK 2,709 M, up from 2,521 M, with a margin of 19.7%.
  • Proposed dividend for fiscal year 2020/21 is SEK 2.20 per share, an increase from SEK 1.80.
  • Cash flow after continuous investments improved to SEK 1,706 M.
Negative
  • Net sales in Q4 decreased to SEK 3,667 M from SEK 4,008 M, a 1% growth in constant currency.
  • Gross margin declined to 38.5% from 42.6% in Q4.
  • Earnings per share decreased to SEK 0.89 from SEK 1.07 in Q4.

STOCKHOLM, May 28, 2021 /PRNewswire/ -- During Elekta's fourth quarter, we drove strong order growth in all regions – both from market growth and market share gain – and we received our 100th Unity order. Installation volumes were similar to levels in the fourth quarter last year, still impacted by reduced access to hospitals, especially in emerging markets due to Covid. When summarizing the full year, we showed good order growth in a pandemic affected market, improved our EBITA on stable volumes and delivered our best annual cash flow ever.

Gustaf Salford

President and CEO

Fourth quarter

  • Gross order intake amounted to SEK 5,379 M (5,032), corresponding to an 18 percent increase in constant currency
  • Net sales were SEK 3,667 M (4,008), corresponding to a 1 percent growth in constant currency
  • Gross margin amounted to 38.5 (42.6) percent
  • EBITA amounted to SEK 743 M (886), corresponding to an EBITA margin of 20.3 (22.1) percent
  • Earnings per share was SEK 0.89 (1.07) before/after dilution
  • Cash flow after continuous investments decreased by SEK 208 M to SEK 818 M (1,026)

Full year

  • Gross order intake amounted to SEK 17,411 M (17,735), corresponding to a 6 percent growth in constant currency
  • Net sales were SEK 13,763 M (14,601), corresponding to a 1 percent increase in constant currency
  • Gross margin amounted to 40.8 (42.0) percent
  • EBITA amounted to SEK 2,709 M (2,521), corresponding to an EBITA margin of 19.7 (17.3) percent
  • Earnings per share was SEK 3.28 (2.84) before/after dilution
  • Cash flow after continuous investments improved by SEK 1,454 M to SEK 1,706 M (252)

Dividend for fiscal year 2020/21

  • The Board of Directors proposes a dividend of SEK 2.20 (1.80) per share (in two instalments) for the fiscal year 2020/21

New mid-term outlook

  • Net sales CAGR of above 7 percent until 2024/25
  • EBIT margin percent expansion until 2024/25
  • A new dividend policy of at least 50 percent of net profit for the year

No significant events after the quarter

1 After continuous investments. 2 Before / after dilution. 3 Based on constant currency.

# # #

For further information, please contact:

Cecilia Ketels, Head of Investor Relations

Tel: +46 76 611 76 25, e-mail: cecilia.ketels@elekta.com

Time zone: CET: Central European Time

Johan Adebäck, CFO, Elekta AB (publ)

Tel: +46 70 873 33 21, e-mail: johan.adeback@elekta.com

Time zone: CET: Central European Time

This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 07:30 CET on May 28, 2021. (REGMAR) 

About Elekta

For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.

CONTACT:

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/elekta/r/year-end-report--may-april-2020-21,c3355662

The following files are available for download:

https://mb.cision.com/Main/35/3355662/1424016.pdf

Elekta Q4 Report 20_21

https://news.cision.com/elekta/i/group-summary-2020-21,c2918171

Group summary 2020/21

 

Cision View original content:http://www.prnewswire.com/news-releases/year-end-report-mayapril-202021-301301512.html

SOURCE Elekta

FAQ

What was Elekta's gross order intake for Q4 2021?

Elekta's gross order intake for Q4 2021 was SEK 5,379 M, an 18% increase in constant currency.

How much did Elekta's net sales increase in fiscal year 2020/21?

Elekta's net sales for fiscal year 2020/21 were SEK 13,763 M, reflecting a 1% increase in constant currency.

What is Elekta's proposed dividend for the fiscal year 2020/21?

Elekta's Board of Directors proposed a dividend of SEK 2.20 per share for fiscal year 2020/21.

What is Elekta's new mid-term outlook for sales growth?

Elekta aims for net sales CAGR of over 7% until 2024/25.

What was the EBITA margin for Elekta in fiscal year 2020/21?

Elekta's EBITA margin for the full year was 19.7%, up from 17.3% the previous year.

ELEKTA B SHS UNSP/ADR

OTC:EKTAY

EKTAY Rankings

EKTAY Latest News

EKTAY Stock Data

2.80B
367.10M
0.01%
Medical Instruments & Supplies
Healthcare
Link
United States of America
Stockholm